Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Public ADS sale nets $109mm for Autolus

Executive Summary

Autolus Therapeutics PLC (T-cell reprogramming for cancer treatment) netted $109mm through the public sale of 4.83mm American Depositary Shares (including the overallotment; representing 4.83mm common) at $24. Offering proceeds will be combined with the company's over $200mm in cash on hand to support continued project development, with the majority earmarked for continued trials of AUTO1 for adult acute lymphocytic leukemia (ALL), AUTO3 for pediatric ALL and diffuse large B-cell lymphoma (DLBCL), AUTO2 for multiple myeloma, and AUTO4 for peripheral T-cell lymphoma.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies